CytomX Therapeutics (CTMX) Income towards Parent Company (2014 - 2026)

CytomX Therapeutics has reported Income towards Parent Company for 13 years, with the latest figure at -$18.2 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 177.57% year-over-year to -$18.2 million; the trailing twelve-month figure through Mar 2026 stood at -$59.1 million (down 242.16% YoY), and the FY2025 full-year result was -$17.4 million, down 154.5% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$18.2 million, up from -$26.5 million in the prior quarter.
• The five-year high for Income towards Parent Company was $23.5 million in Q1 2025, with the low at -$32.0 million in Q1 2022.
• Historically, Income towards Parent Company has averaged -$6.1 million across 5 years, with a median of -$3.3 million in 2023.
• The largest YoY upside for Income towards Parent Company was 2155.2% in 2024 against a maximum downside of 501.1% in 2024.
• CytomX Therapeutics' Income towards Parent Company stood at -$8.8 million in 2022, then soared by 109.54% to $837000.0 in 2023, then jumped by 2155.2% to $18.9 million in 2024, then tumbled by 240.44% to -$26.5 million in 2025, then jumped by 31.17% to -$18.2 million in 2026.
• The last three Income towards Parent Company figures came in at -$18.2 million (Q1 2026), -$26.5 million (Q4 2025), and -$14.2 million (Q3 2025), per Business Quant data.